Kinnate Biopharma Inc. Common Stock
KNTE
KNTE was delisted on the 2nd of April, 2024.
71 hedge funds and large institutions have $270M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 14 closing their positions.
274% more call options, than puts
Call options by funds: $277K | Put options by funds: $74K
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
9% more capital invested
Capital invested by funds: $249M → $270M (+$21.6M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
9% less funds holding
Funds holding: 78 → 71 (-7)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$6.7M |
| 2 |
O
OrbiMed
New York
|
+$6.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$5.5M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.32M |
| 5 |
Goldman Sachs
New York
|
+$899K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.69M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$1.96M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$825K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$433K |
| 5 |
BlackRock
New York
|
-$358K |
KNTE Hedge Fund Activity: Q1 2023 in Review
71 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q1 2023, worth a combined $270M — up 8.7% from $249M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of KNTE and 7 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 24 added.
The largest buyer was Foresite Capital Management V, adding an estimated $6.7M. The largest seller was Fidelity Investments, cutting an estimated $2.69M.
- 71 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q1 2023, down from 78 in Q4 2022.
- Funds reported $270M of Kinnate Biopharma Inc. Common Stock stock for Q1 2023, up 8.7% quarter-over-quarter.
- 7 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q1 2023 and 14 closed out, a net change of -7 holders.
- The largest Kinnate Biopharma Inc. Common Stock buyer in Q1 2023 was Foresite Capital Management V, an estimated $6.7M added.
- The largest Kinnate Biopharma Inc. Common Stock seller in Q1 2023 was Fidelity Investments, an estimated $2.69M sold.
Based on aggregated 13F filings for Q1 2023.